Swiss drugmaker Novartis increases 2024 profit guidance due to higher Entresto and Kesimpta prescriptions.
Swiss drugmaker Novartis raised its 2024 profit guidance for the second time, driven by increased prescriptions of key drugs including heart failure treatment Entresto and multiple sclerosis drug Kesimpta. Novartis now expects its core operating profit to grow in the mid to high teens, up from a low double-digit to mid-teens range previously. The company's full-year sales growth remains in a high-single to low-double-digit range.
July 18, 2024
13 Articles